Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies, Swisstec Ink Asian Distribution Deal

NEW YORK (GenomeWeb) – Genetic Technologies announced today that it has granted the nonexclusive distribution rights for its genetic screening tests in Asia to Swisstec Health Analytics.

Fitzroy, Australia-based Genetic Technologies offers the BrevaGenplus breast cancer risk assessment test and is developing additional cancer risk assessment products including one for colorectal cancer.

Under the terms of the deal, Swisstec will have the nonexclusive rights to distribute the tests to hospital networks in Asia. In exchange, Genetic Technologies will receive a 5 percent equity stake in Swisstec, and may acquire an additional 5 percent based on the achievement of certain undisclosed milestones. Genetic Technologies has also agreed to provide Swisstec with A$250,000 ($185,238) to facilitate its expansion into China.

The distribution deal comes a little more than month after Genetic Technologies and Swisstec agreed to form a joint venture that will develop a service platform using blockchain technology for medical services and personalized health management. As part of that collaboration, Genetic Technologies will receive a 20 percent stake in Swisstec.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.